Silver D - Search Results

1

Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.

Wilson RE, Seeberger LC, Silver D, Griffith A, Conner JB, Salzman PM; LEGATO Investigators. Wilson RE, et al. Among authors: silver d. Neurologist. 2011 Nov;17(6):318-24. doi: 10.1097/NRL.0b013e31822f6872. Neurologist. 2011. PMID: 22045282 Clinical Trial.

2

Impact of functional age on the use of dopamine agonists in patients with Parkinson disease.

Silver D. Silver D. Neurologist. 2006 Jul;12(4):214-23. doi: 10.1097/01.nrl.0000215782.78763.fa. Neurologist. 2006. PMID: 16832240 Review.

3

Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.

Silver DE, Buck PO. Silver DE, et al. Int J Neurosci. 2011 Sep;121(9):485-9. doi: 10.3109/00207454.2011.582240. Epub 2011 Jun 15. Int J Neurosci. 2011. PMID: 21671840 Review.

4

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.

Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, Sussman NM. Stacy M, et al. Among authors: silver d. Neurology. 2008 Jun 3;70(23):2233-40. doi: 10.1212/01.wnl.0000313834.22171.17. Neurology. 2008. PMID: 18519872 Clinical Trial.

5

Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.

Stacy M, Silver D. Stacy M, et al. Among authors: silver d. Parkinsonism Relat Disord. 2008;14(2):85-92. doi: 10.1016/j.parkreldis.2007.07.016. Epub 2007 Dec 21. Parkinsonism Relat Disord. 2008. PMID: 18083605 Review.

6

Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.

Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S; ANDANTE study investigators. Hauser RA, et al. Among authors: silver d. Mov Disord. 2014 Jul;29(8):1028-34. doi: 10.1002/mds.25877. Epub 2014 Jun 11. Mov Disord. 2014. PMID: 24919813 Free article. Clinical Trial.

7

Early, nondisabling Parkinson's disease: weighing the options for initial therapy.

Silver DE. Silver DE. Neurol Clin. 2008 Aug;26(3 Suppl):S1-13, v. doi: 10.1016/j.ncl.2008.05.004. Neurol Clin. 2008. PMID: 18774439 Review.

8

Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease.

Ondo WG, Hunter C, Isaacson SH, Silver DE, Stewart RM, Tetrud JW, Davidson A. Ondo WG, et al. Parkinsonism Relat Disord. 2011 Feb;17(2):117-8. doi: 10.1016/j.parkreldis.2010.10.001. Epub 2010 Nov 16. Parkinsonism Relat Disord. 2011. PMID: 21084213 Clinical Trial.

9

Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).

Silver DE. Silver DE. Expert Rev Neurother. 2004 Jul;4(4):589-99. doi: 10.1586/14737175.4.4.589. Expert Rev Neurother. 2004. PMID: 15853578 Review.

10

Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis.

Baker WL, Silver D, White CM, Kluger J, Aberle J, Patel AA, Coleman CI. Baker WL, et al. Among authors: silver d. Parkinsonism Relat Disord. 2009 May;15(4):287-94. doi: 10.1016/j.parkreldis.2008.07.004. Epub 2008 Sep 6. Parkinsonism Relat Disord. 2009. PMID: 18774743

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

840 results

Search Page

Filters